LIMINIB program’s goal is to develop a first in class selective inhibitor of LIM Kinase to treat high unmet need cancers such as leukemias.
The rationale behind the program and an overview of the preclinical proof of concept were published Dr Prudent and Lafanechère et al. in Cancer Research in October 2012.
In a nutshell, our first Hit from the LIMINIB program named LIM-Pyr1 is a selective LIMK inhibitor that has shown potent indirect microtubule stabilization as well as actin filament disruption (see below).
After discontinuation of our first Hit from the LIMINIB program named LIM-Pyr1 in 2015, we generated new assets through a rationale drug design chemistry program and subsequent Hit to Lead optimisation. IP on these compounds belongs exclusively to CELLIPSE. Our most advanced Lead Candidate called CEL_Amide is a dual LIMK 1/2 inhibitor that has shown to be much more potent and selective than LIM-Pyr1 with pharmacological properties suitable for clinical drug development.
We are currently collaborating with leading Research Labs and Academic Teams throughout in Europe, the USA on understanding better the role of LIM K in cancer physiopathology. If you are interested by such collaboration, do not hesitate to reach out to us.